Skip to main content
TipRanks
Go Ultimate75% OFF

Healthpeak Properties (HC5) Q3 2026 Earnings Report

1 Followers

DE:HC5 Q3 2026 EPS Results

Actual EPS
EUR 0.02
Consensus EPS
EUR 0.06
Beat/Miss
Missed by -EUR 0.04
One Year Ago EPS
-EUR 0.15

DE:HC5 Q3 2026 Revenue Results

Actual Revenue
EUR 744.75M
Expected Revenue
EUR 670.62M
Beat/Miss
Beat by +EUR 74.13M
YoY Revenue Growth
+16.29%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/02/2026
Time
After Close
Conference Call
Monday, November 2, 2026
DE:HC5 Upcoming Earnings

Healthpeak Properties's next earnings date is estimated for February 8, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:HC5 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 02, 2026|% Change Since:0.60%|
Earnings Call Sentiment|Positive

The call was strongly constructive. Management reported broad operational outperformance, multiple guidance increases, improving occupancy and leasing across outpatient and life science, substantial senior housing growth, attractive acquisition opportunities, and significant liquidity. The principal challenges were higher refinancing costs, $1.4 billion of 2027 maturities, the lag between life science leasing and cash flow, continued lab same-store NOI declines, and transaction-market volatility. Overall, the highlights significantly outweighed the lowlights.

Company Guidance

Healthpeak raised FFO as adjusted guidance for the third consecutive quarter by $0.02 at the midpoint to a range of $1.76-$1.78 per share, with total same-store guidance increased by 50 basis points at the midpoint to a range of 0.5%-2.0%, including outpatient medical of 2.5%-3%, lab of down 3% to down 6%, and senior housing of 16%-19%; the company also said it increased earnings guidance for the third time this year, by a total of $0.05 per share at the midpoint. For 2027, Healthpeak expects internal growth to accelerate, sees a real chance to materially move total occupancy higher in outpatient, and is generally underwriting life science acquisitions to fully lease up in the two to three year range, with 9%-10% stabilized yields and stabilized occupancy more in the 90% range for the three acquisitions. The company expects $400 million of term loans to be drawn in the fourth quarter and $500 million in the first quarter of 2027, against $1.4 billion in maturities in 2027, and expects CapEx consistent with years past without an expectation for CapEx dramatically in excess of where we are today.

  • Strong Quarter and Raised Annual GuidanceManagement described the quarter as operationally very strong and raised earnings guidance for the third time in 2026, by a total of $0.05 per share at the midpoint. The increases were primarily driven by portfolio operations and the flow-through impact of Janus Living.
  • Solid Core Financial MetricsThird-quarter FFO as adjusted was $0.44 per share, total same-store cash NOI growth was 3.6%, and net debt to adjusted EBITDA was 4.7x.
  • Outpatient Medical Demand Remains StrongManagement said cost pressures are making outpatient delivery a strategic mandate for health systems, while the aging population is driving record demand and supply remains at historical lows.
  • Outpatient Leasing Execution and RetentionHealthpeak executed 846,000 square feet of outpatient leases during the quarter, including 218,000 square feet of new leasing and 628,000 square feet of renewals. Year-to-date executions reached 3.2 million square feet. Tenant retention increased to 81.7%, cash releasing spreads were approximately 5% above historical averages, and average leasing costs on renewals were modest at 9.5% of rents.
  • Outpatient Lease Quality and Future GrowthNew outpatient lease commencements averaged more than 11 years and included two large health system and physician practice master leases at rents above $30 per square foot on a triple-net basis. Management expects internal growth to accelerate in 2027 based on recent lease executions and the leasing pipeline.
  • Outpatient Leasing Pipeline and Occupancy ProgressThe outpatient portfolio ended the quarter at 90.3% total occupancy. Entering the fourth quarter, Healthpeak had an additional 269,000 square feet of executed leases and 1.03 million square feet of signed LOIs. Management said total occupancy had increased for two consecutive quarters excluding transaction impacts and that it saw a meaningful opportunity to increase occupancy in 2027.
  • Successful Outpatient MonetizationsHealthpeak closed nearly $2 billion of fully stabilized outpatient sales, recapitalizations, and loan repayments earlier in the year at a blended 6% cap rate. More than half of the proceeds came from joint venture recapitalizations with blue-chip limited partners that chose to partner with Healthpeak.
  • Life Science Occupancy OutperformanceLife science total occupancy increased 130 basis points sequentially in the third quarter and 270 basis points year to date, reaching 79.8%. This exceeded management's earlier expectation of 100 basis points of occupancy growth for 2026.
  • Improving Life Science Demand and Supply DynamicsLife science job growth turned positive in the third quarter, consistent with improving demand in the pipeline. Management also said certain life science buildings are moving to alternative uses, including AI-adjacent users and robotics, which is absorbing some vacancy. These uses are attracted by lab-building infrastructure such as power, floor loads, and ceiling heights.
  • Torrey Pines Reached Full OccupancyHealthpeak said its Torrey Pines portfolio is now fully leased, compared with 65% leased in that submarket six months earlier. Management said the stronger occupancy should support better economics on future leases.
  • Strong Gateway Campus LeasingAt the Gateway campus acquired earlier in the year, Healthpeak signed 125,000 square feet of leases during the first quarter of the fourth quarter, with another 100,000 square feet under signed LOI or in active discussions.
  • Life Science Leasing Volume AcceleratedHealthpeak executed 480,000 square feet of life science leases during the quarter, its strongest quarter in more than a year, bringing year-to-date executed leases to more than 1 million square feet. Approximately 70% represented new leasing, more than 80% involved biotechnology and R&D tenants, and more than 40% involved vacant space. An additional 643,000 square feet of leases and signed LOIs was reported after quarter end.
  • Positive Life Science Net Absorption and Leasing PipelineThe life science portfolio achieved a third consecutive quarter of positive net absorption. Management said 50% of executions and active discussions involve existing clients and 50% involve new clients, with demand coming from both biotechnology and technology-adjacent users across the company's markets.
  • Improved Life Science Tenant Credit ConditionsManagement cited more than $150 billion of capital flowing into biotechnology through IPOs, M&A, and secondary offerings. It said the stronger capital-markets environment has benefited tenant demand, enabled existing tenants to access capital, and meaningfully improved the overall credit profile of the lab portfolio.
  • Attractive Life Science Acquisition OpportunityHealthpeak said it has approximately $1 billion of life science acquisitions either closed or in the pipeline, generally located within or adjacent to existing Healthpeak campuses. Management said the assets can be acquired at low prices while remaining strategically important to the existing portfolio.
  • High Stabilized Yield Potential on AcquisitionsThe three announced life science acquisitions are currently 41% occupied, with a 5% in-place yield expected to reach 9%-10% at stabilization. Healthpeak said it already has strong leasing activity on 70% of the acquired vacancy and is generally underwriting full lease-up in the two to three year range.
  • Strategic Shift Toward Fee-Simple Life Science AcquisitionsAfter previously favoring structured investments such as mortgage lending and preferred stock, Healthpeak said 2026 pricing had fallen sufficiently for it to shift toward fee-simple acquisitions that can support compelling stabilized returns at today's market rents.
  • Growing Life Science PlatformManagement said Healthpeak entered the 2022 life science downturn as the number three player and is entering the recovery as the only company in the sector growing its footprint and adding talent. The company said it is progressing toward becoming the leading life science real estate portfolio and platform.
  • Senior Housing Operating MomentumJanus Living's same-store portfolio delivered 300 basis points of occupancy growth and 26% NOI growth in the quarter. Third-quarter entry fee sales reached a new all-time high for the quarter.
  • Janus Living Revenue and EBITDA GrowthJanus Living delivered 26% same-store NOI growth, 78% total revenue growth, and 101% adjusted EBITDAre growth during the quarter.
  • Janus Living Acquisition and Partner ExpansionJanus Living completed the acquisition of 39 communities totaling approximately $2.1 billion during the quarter and through October, bringing year-to-date acquisitions to $2.9 billion. Since the IPO, Healthpeak has closed $2.2 billion of acquisitions, with deal NOI trending in line with or ahead of underwriting. Janus expanded from two operating partners to 13, increasing its external-growth opportunities.
  • Liquidity and Proactive Financing ActionsHealthpeak had approximately $3.8 billion of liquidity as of October 30 and had originated $900 million of delayed-draw term loans: a $400 million term loan expected to be drawn in the fourth quarter and a $500 million term loan expected to be drawn in the first quarter of 2027. Both were priced at SOFR plus 80 basis points, inside current bond-issuance levels.
  • Raised FFO and Same-Store GuidanceHealthpeak raised 2026 FFO as adjusted guidance for the third consecutive quarter by $0.02 per share at the midpoint to a range of $1.76-$1.78 per share. Total same-store guidance increased by 50 basis points at the midpoint to 0.5%-2.0%, including outpatient medical guidance of 2.5%-3%, lab guidance of down 3% to down 6%, and senior housing guidance of 16%-19%.
  • AI and Robotics Demand Adds Leasing OpportunitiesManagement said AI and robotics users are creating purely incremental demand in some cases, taking space that is in shell condition or not built out as lab space at competitive rents and lower tenant-improvement costs. These users are also absorbing buildings that otherwise might have been converted to lab space.
  • Strong Leasing Economics in Selected MarketsManagement said it has recently seen multiple tenants bidding for the same suite or building, a dynamic not seen in several years. It also said the Bay Area portfolio often achieves better rental rates than the market through existing-tenant relationships, while Torrey Pines' full occupancy should provide additional pricing power.
  • Outpatient Disposition PipelineHealthpeak expects to complete approximately $200 million of additional outpatient asset sales by year-end. The assets comprise four Southeast buildings where a health system was considering whether to renew; management said the properties were not particularly strategic and were sold at a fair and reasonable price.

DE:HC5 Earnings History

DE:HC5 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 08, 20272026 (Q4)0.03-0.15――
Nov 02, 20262026 (Q3)0.060.02-0.15111.76% (+0.17)
Aug 04, 20262026 (Q2)0.030.070.0560.00% (+0.03)
May 05, 20262026 (Q1)0.050.250.05366.67% (+0.20)
Feb 02, 20262025 (Q4)0.060.150.011500.00% (+0.14)
Oct 23, 20252025 (Q3)0.05-0.150.11-241.67% (-0.26)
Jul 24, 20252025 (Q2)0.060.050.19-76.19% (-0.15)
Apr 24, 20252025 (Q1)0.050.050.01500.00% (+0.05)
Feb 03, 20252024 (Q4)0.040.010.12-92.31% (-0.11)
Oct 24, 20242024 (Q3)0.060.110.110.00% (+0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed